Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445877 in Advanced Solid Tumors
NCT05584670Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Nov 2022
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 6
01
Overview
A Phase 2 trial of SAR445877 in solid tumor, melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), sponsored by Sanofi. Started Nov 2022; status: recruiting.
02
Drugs
SAR445877
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05584670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584670.